Cancer Center Jobs

Vice Chair, Bone Marrow Transplant and Cellular Therapies (inaugural)

Fox Chase Cancer Center, Temple Health

October 13, 2024
A commitment to succession planning and strategic expansion initiatives has created an outstanding opportunity for a visionary leader to significantly influence the future of blood cancer treatment, research and education at Fox Chase Cancer Center and Temple Health as the inaugural Vice Chair, Bone Marrow Transplant and Cellular Therapies.

The Opportunity

Already recognized as one of the leading programs in the country for the treatment of blood cancers, Fox Chase Temple Health is now creating the TUHS Blood Disorders Institute. The vision of this initiative is to establish Fox Chase Temple Health as the national leader in the diagnosis, treatment, research, and education of hematologic malignancies, cellular therapy, and related blood disorders.

With the Institute as a leading priority for the institution, and with the resources and support from the Department of Bone Marrow Transplant and Cellular Therapies, Fox Chase Cancer Center, and Temple Health, the new Vice Chair will be positioned to lead and achieve key initiatives and goals including optimization and integration of the department’s clinical operations across the care continuum, programmatic expansion and strategic planning for the Department, and further development the Department’s research portfolio, including leadership of translational and clinical research.  In addition, the Vice Chair will play an integral role in developing a new institute dedicated to advancing research and treatment of blood disorders.

The Ideal Candidate

The successful candidate will be an innovative and collaborative leader with experience in bone marrow transplant services and a proven track record of leadership and clinical excellence. They will be passionate about the tripartite mission and have the charisma to lead and represent the organization to the community. Progressive administrative and operational experience working in an NCI-designated cancer center, with a concomitant understanding of the complexities of delivering care in a large system that supports research innovation, is essential. This leader will have a history of extramural funding, particularly in therapeutics or outcomes, with experience and knowledge in Investigator-Initiated clinical trials, National Clinical Trials Network, and industry-sponsored trials. MD, DO or MD/PHD, and medical oncology board certification required. Fellowship training in Bone Marrow Transplant is required. A record of achievement suitable for appointment as Associate Professor or Professor is needed and must be eligible for licensure in Pennsylvania. 

The Organization

Fox Chase Cancer Center is a founding member of the National Comprehensive Cancer Network and provides patient care and research in more than 80 laboratories with more than 2,000 staff, physicians, and scientists. Researchers at Fox Chase have won the highest awards in their fields, including two Nobel Prizes, a Kyoto Prize in basic sciences, a Lasker Clinical Research Award, an Albert Szent-Györgyi Prize for Progress in Cancer Research, American Cancer Society Medals of Honor, memberships in the National Academy of Sciences, induction into the National Inventors Hall of Fame, and more. Today, scientific initiatives span a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. The past few years have seen significant advances in Fox Chase’s clinical, operational, research, and financial performance.

Fox Chase’s affiliation with Temple University (TU) and Temple University Health System (TUHS) and the Lewis Katz School of Medicine began in 2012. Through this arrangement, Fox Chase combines the flexibility of a free-standing cancer center with the scientific and clinical power of a large academic health system. Over the past decade, the size and scope of Fox Chase have expanded in terms of its scientific portfolio, the number of patients served, and the diversity of its patient population: capital upgrades and investments in new technology and physical plant enhancements.

Nominations are greatly appreciated and may be sent to:

Ellen Lockhart, MD, Principal

Rachael Burns, Vice President

Charlotte Tinsley, Consultant

c/o  [email protected]

Executive & Physician Leadership Search, AMN Leadership Solutions, AMN Healthcare